A Review on Molecular Mechanisms of Antifungal Resistance in Candida glabrata : Update and Recent Advances
Candida glabrata is the second frequent etiologic agent of mucosal and invasive candidiasis. Based on the recent developments in molecular methods, C. glabrata has been introduced as a complex composed of C. glabrata, Candida nivariensis, and Candida bracarensis. The four main classes of antifungal drugs effective against C. glabrata are pyrimidine analogs (flucytosine), azoles, echinocandins, and polyenes. Although the use of antifungal drugs is related to the predictable development of drug resistance, it is not clear why C. glabrata is able to rapidly resist against multiple antifungals in clinics. The enhanced incidence and antifungal resistance of C. glabrata and the high mortality and morbidity need more investigation regarding the resistance mechanisms and virulence associated with C. glabrata; additional progress concerning the drug resistance of C. glabrata has to be further prevented. The present review highlights the mechanism of resistance to antifungal drugs in C. glabrata.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Microbial drug resistance (Larchmont, N.Y.) - 27(2021), 10 vom: 15. Okt., Seite 1371-1388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lotfali, Ensieh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.01.2022 Date Revised 25.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/mdr.2020.0235 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325084785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325084785 | ||
| 003 | DE-627 | ||
| 005 | 20231225191704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/mdr.2020.0235 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325084785 | ||
| 035 | |a (NLM)33956513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lotfali, Ensieh |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Review on Molecular Mechanisms of Antifungal Resistance in Candida glabrata |b Update and Recent Advances |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2022 | ||
| 500 | |a Date Revised 25.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Candida glabrata is the second frequent etiologic agent of mucosal and invasive candidiasis. Based on the recent developments in molecular methods, C. glabrata has been introduced as a complex composed of C. glabrata, Candida nivariensis, and Candida bracarensis. The four main classes of antifungal drugs effective against C. glabrata are pyrimidine analogs (flucytosine), azoles, echinocandins, and polyenes. Although the use of antifungal drugs is related to the predictable development of drug resistance, it is not clear why C. glabrata is able to rapidly resist against multiple antifungals in clinics. The enhanced incidence and antifungal resistance of C. glabrata and the high mortality and morbidity need more investigation regarding the resistance mechanisms and virulence associated with C. glabrata; additional progress concerning the drug resistance of C. glabrata has to be further prevented. The present review highlights the mechanism of resistance to antifungal drugs in C. glabrata | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Candida bracarensis | |
| 650 | 4 | |a Candida glabrata | |
| 650 | 4 | |a Candida nivariensis | |
| 650 | 4 | |a antifungal resistance | |
| 650 | 4 | |a azole | |
| 650 | 4 | |a echinocandin | |
| 650 | 4 | |a polyene | |
| 650 | 4 | |a pyrimidine analogues | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Polyenes |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 700 | 1 | |a Fattahi, Azam |e verfasserin |4 aut | |
| 700 | 1 | |a Sayyahfar, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Rabiei, Mohammad Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Fathi, Mobina |e verfasserin |4 aut | |
| 700 | 1 | |a Vakili, Kimia |e verfasserin |4 aut | |
| 700 | 1 | |a Deravi, Niloofar |e verfasserin |4 aut | |
| 700 | 1 | |a Soheili, Amirali |e verfasserin |4 aut | |
| 700 | 1 | |a Toreyhi, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Shirvani, Fariba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbial drug resistance (Larchmont, N.Y.) |d 1997 |g 27(2021), 10 vom: 15. Okt., Seite 1371-1388 |w (DE-627)NLM090651677 |x 1931-8448 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:10 |g day:15 |g month:10 |g pages:1371-1388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/mdr.2020.0235 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 10 |b 15 |c 10 |h 1371-1388 | ||